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Internal tandem duplication (ITD) mutations in the juxtamembrane domain of the fms-like 
tyrosine kinase 3 (FLT3) gene occur in approximately one quarter of cases of acute myeloid leukemia 
(AML)1, are associated with constitutive activation of the kinase2 and confer a poor prognosis3. Our 
understating of the molecular consequences of these mutations has benefited from studies of 
bespoke mouse models
4-6
. Herein we report the identification of the germline variant F692L in cis 
with the Flt3-ITD allele of the widely studied Flt3tm1Dgg mouse4. As this variant is analogous to the 
human FLT3 F691L “gatekeeper” mutation3 we investigated this finding further. We found that 




 double mutant mice are resistant to Sorafenib and 
Quizartinib (AC220), but sensitive to Ponatinib. The same pattern of sensitivity was observed when 
we tested these tyrosine kinase inhibitors (TKIs) against isogenic Ba/F3 cells transfected with the 
murine Flt3-ITD F692L or the reverted Flt3-ITD wildtype cDNAs, confirming that Flt3-ITD F692L is 
responsible for recapitulating the resistance pattern of the human F691L mutation. The presence of 
this Flt3 TKI resistant variant needs to be considered when interpreting data using this model, but 
also makes the model an extremely useful tool for studying TKI resistance. 
The molecular consequences of FLT3-ITD are pleiotropic and include activation of STAT5 via 
the SRC kinase, phosphorylation of the transcription factor FOXO3A with associated activation of Akt 
and induction of reactive oxygen species, amongst others (reviewed by Yeung et al
3
). Knock-in 
mouse models have been instrumental in deciphering the hematopoietic and leukemogenic effects 
of FLT3-ITD alone4-6 and in combination with mutations co-occurring with FLT3-ITD in human AML7-
12
; as well as in studying the effectiveness of different therapeutic approaches against FLT3-ITD 
positive leukaemias 11, 13. As part of these efforts, we studied the powerful collaboration between 
FLT3-ITD and mutant NPM1, by crossing our conditional Npm1flox-cA knock-in14 with the Flt3-ITD 
knock-in mice (Flt3tm1Dgg) generated by Lee et al 4. Triple transgenic Npm1flox-cA/+; Flt3ITD/+; Mx1-Cre+ 
rapidly succumbed to AML with a median latency of 49 days, exhibiting full recombination of the 
conditional Npm1flox-cA allele without the need to induce Mx1-Cre expression with polyinosinic-
polycytidylic acid as previously published 8.  To identify or exclude additional cooperating somatic 




ITD/+; Mx1-Cre+ AMLs. Comparison with constitutional (tail) exome sequence from C57BL/6N mice 
identified a common variant located at Chr5:147349699 (GRCm38), within exon 17 of the Flt3 gene. 
The variant, Flt3 c.2076 T>A (p.F692L), was present at VAFs of 0.55-0.94. Using PCR-amplification 
followed by MiSeq sequencing we found that these VAFs correlated strongly with those of the Flt3-
ITD allele itself (Figure 1A). As the Flt3-ITD mutation is located at exon 14 and frequently exhibits loss 
of heterozygosity in our model8 this indicated that the F692L variant is present in cis with the knock-





Flt3 F692L variant in Flt3-ITD knock-in mice 
 
single transgenic mice from our cohort (Figure 1B). Furthermore, we identified the same variant in 
germline DNA from the cohorts of two separate research groups who obtained the Flt3-ITD mouse 
model independently (Supplementary Figure 1). 
As the murine F692L variant is equivalent to the human F691L gatekeeper mutation, which 
confers AML resistance to multiple FLT3 tyrosine kinase inhibitors (TKI)3, 15,  we proceeded to test 
whether this was also true of the murine variant. To do this we cultured AML cells from two 
independent Npm1cA/+; Flt3ITD/+; Mx1-Cre+ mice8 in X-VIVO media (Lonza, Switzerland) supplemented 
with murine IL-3, IL-6 and SCF (Miltenyi, Germany). After 72hr in culture, we removed IL-3 and 
exposed the cells to varying concentrations of Quizartinib (AC220), Sorafenib and Ponatinib for three 
days, using the human FLT3-ITD positive AML cell line MV4-11 as a positive control. After three days 
of treatment, cell viability was assessed using the CellTiter 96® AQueous assay (Promega, USA). We 
found that, compared to MV4-11, Npm1cA/+; Flt3ITD/+; Mx1-Cre+ AML cells exhibit resistance to 
Quizartinib and Sorafenib, but not to Ponatinib which is known to retain activity against the human 
FLT3-ITD F691L mutant isoform15, 16 (Figure 2A)  
To exclude the possibility that our murine AMLs and MV4-11 displayed different resistance 
patterns for reasons other than the F692L mutation, we amplified the full open-reading frame of the 
Flt3 cDNA from bone marrow mRNA of homozygous Flt3ITD/ITD mice and cloned this into an MSCV-
CFP retroviral backbone (kind gift of Dr Brian Huntly, University of Cambridge) (Figure 2B). We then 
also generated a reverted c.2076A>T (Flt3-ITDF692F) construct in the same MSCV-CFP retroviral 
backbone using Gibson assembly (see Supplementary Methods). The two retroviruses were each 
used to transduce IL-3 dependent CellSensor® irf-bla Ba/F3 cells (Invitrogen, Carlsbad), which were 
subsequently sorted to >95% purity (Supplemental Methods and Supplementary Figure 2A). The 
Flt3-ITD
F692L
 cDNA- and the Flt3-ITDF692F cDNA-transfected cells displayed comparable IL-3 
independent growth (Figure 2B) and FRET assays showed concomitant activation of the JAK/STAT 
pathway, recapitulating the effects of human FLT3-ITD mutants (Supplementary Figure 2B). Next, we 
treated the transformed Ba/F3 cell lines as described above for the primary AML cells. This 
demonstrated that cells transformed with Flt3-ITDF692L were resistant to AC220 and Sorafenib, but 
not Ponatinib, unlike wild-type Flt3
ITDp.F692F 
cells that were sensitive to all three compounds (Figure 
2C). These data, taken together with our results with the primary AML cells, confirm that the murine 
F692L mutation mimics the properties of the human F691L mutant FLT3-ITD and confers a similar 
profile of resistance to FLT3 inhibitors16. 
Here, we show that the Flt3tm1Dgg knock-in mice carry the Flt3 F692L resistance variant in cis 
with the human W51 Flt3-ITD mutation. The variant corresponds to the human F691L and shares at 
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least some of its drug sensitivity/resistance profile. The origin of the c.2076A>T (p.F692L) variant 
within the Flt3
tm1Dgg
 allele is not clear. Examination of the strategy and design of the original gene 
targeting construct revealed that this did not extend to exon 17, which contains codon F692. 
Therefore, it appears unlikely that the c.2076T>A SNV was introduced into the mouse Flt3 locus 
during gene targeting
4
. Also, the presence of the variant in 3/3 independent Flt3
tm1Dgg 
mouse 
colonies tested, rules out the possibility that the SNV was uniquely acquired in our cohort. 
Therefore, the SNV was either present in the original embryonic stem cells used to generate the 
knock-in mice or was acquired in the germline during the expansion of the original colony. Notably 
the SNV is not present in any of the 48 sequenced mouse strains according to the mouse genome 
informatics (MGI) database (http://www.informatics.jax.org/javawi2/servlet/WIFetch?page=snpQF). 
Nevertheless, regardless of its origin, the presence of this variant needs to be taken into account 




 particularly those 
investigating therapeutic approaches11, 13. Additionally, our findings make the Flt3tm1Dgg model 
particularly useful in the study of novel TKIs such as Ponatinib and PLX3397, which retain activity 
against the human F691L gatekeeper mutation15. Moreover, our findings emphasize the importance 
of careful characterisation of genetically modified mice before drawing conclusions about the 
pathologies they model, particularly when targeted therapeutic interventions are being investigated. 
Whilst in our manuscript the genetic variant influencing drug response was not present in wild-type 
mice, in other cases it can represent a consistent human - mouse difference, as was recently 
described for Lenalidomide and a mouse-specific variant in Cereblon (Crbn) that makes mouse cells 
insusceptible to the drug17. Given the availability and relative affordability of next generation 
sequencing, we propose that genomic characterisation such as exome sequencing, of frequently-
used or novel mouse models should be used to identify coding variants in order avoid 
misinterpretation of findings from these otherwise highly valuable biological reagents.    
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Figure Legends 
Figure 1. Identification of the Flt3 c.2076 T>A (F692L) variant in cis in Flt3-ITD knock-in mice 
(A) The Flt3 c.2076 T>A exon 17 single nucleotide variant (SNV) was identified in 5/5 exomes of 
Npm1
cA/+; Flt3ITD/+; Mx1-Cre+ acute myeloid leukemia (AML) samples at varying variant allele fractions 
(VAF) (left panel). These results were confirmed by PCR-amplification followed by MiSeq sequencing 
of the 5 available AML DNA samples (T1-T5) and this also revealed a close correlation between the 







mice confirmed that the SNV is present in cis with the Flt3tm1Dgg allele and not particular to the 
Npm1
cA; Flt3tm1Dgg double mutant cohort. (C) Protein sequence alignment of mouse and human FLT3 
protein demonstrates mouse p.F692 corresponds to human p.F691, target of the F691L gatekeeper 
TKI resistance mutations.   
 
Figure 2. The Flt3 c.2076 T>A (F692L) variant confers resistance to Quizartinib and Sorafenib  




 mice, were cultured in X-
VIVO-20 medium (Lonza) (supplemented with 5% FCS, 10ng/ml mIL-6 and 50ng/ml mSCF) and 
incubated with Flt3 TKIs over a range of concentrations. IC50 values for each murine leukemia and 
for the control cell line MV4;11, in response to each treatment are displayed. (B) MSCV-Flt3-ITD-CFP 
retroviral constructs used to stably transduce CellSensor® irf-bla Ba/F3 cells. Both the Flt3ITDF692L and 
the reverted Flt3F692F cDNAs transformed the Ba/F3 cells to IL-3 independent growth with growth 
kinetics similar to those of IL-3-stimulated cells transduced with an MSCV-CFP (empty) vector (also 
see Supplementary Figure 2). (C) Stably transduced mutant Ba/F3 cell lines and the FLT3-ITD-positive 
AML cell line MV4;11 were incubated with Flt3 inhibitors at a range of concentrations. The MSCV-
Flt3ITD
F692L
-CFP construct conferred Ba/F3 resistance to both Quizartinib and Sorafinib, but not 
Ponatinib; whilst cells transduced with the MSCV-Flt3ITD
F692F
-CFP construct remained sensitive to all 
three inhibitors.  IC50 values for Flt3ITDp.F692L (blue) or the corrected Flt3ITDp.F692L cDNA (red) 
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Sequencing Validation Primers. 
MiSeq Amplicon Sequencing. 
For generating Variant Allele Frequencies for Flt3-WT and Flt3-ITD alleles in DNA extracted 
from AML samples, the following primers were used. MiSeq adapter sequences are 
underlined; Flt3 locus specific sequences are in bold. 
Flt3_Miseq Fwd: acactctttccctacacgacgctcttccgatctaggtacgagagtcagctgcagatg 
Flt3_Miseq Rev: tcggcattcctgctgaaccgctcttccgatcttgtaaagatggagtaagtgcgggt 
For generating Variant Allele Frequencies for Flt3-WT and Flt3-ITDF692L alleles in DNA 
extracted from AML samples, the following primers were used. MiSeq adapter sequences 
are underlined; Flt3 locus specific sequences are in bold. 
Flt3_Ex17SNP_ Miseq Fwd: acactctttccctacacgacgctcttccgatcttgtctgcagtctgtctaacct 
Flt3_Ex17SNP_Miseq Rev: tcggcattcctgctgaaccgctcttccgatctgtgtgtgcagtggtcattct 
Sanger Sequencing. 
For generating Flt3 Exon 17 sequencing amplicon; 
Flt3_Ex17_Fwd: acagtgctgagatcgagtgt 
Flt3_Ex17_Rev: cttaggtctcaggccacaca 








Cloning of mouse Flt3-ITDp.F692L and Flt3-ITDp.F692F cDNA into the MSCV-CFP retroviral 
backbone. 
mRNA extracted from homozygous Flt3tm1Dgg mouse bone marrow cells was reverse 
transcribed using SuperScript III (Invitrogen) and the subsequent cDNA was used as 
template to amplify the Flt3ITDp.F692L cDNA using high fidelity taq polymerase (KAPA HiFi 
HotStart ReadyMix, Kapa Biosystems) and the following primers; 
MluI-mFLT3ITD3-XhoI Fwd: aattcacgcgtatgcgggcgttggcgcagcgcagcgaccg 
MluI-mFLT3ITD3-XhoI Rev: ggatctctcgagctaacttctttctccgtgaatcttcacc 
This fragment was cloned into the MluI/XhoI linearized fragment of the MSCV-CFP retroviral 
backbone using standard molecular biology techniques. 
A three way Gibson assembly was used to clone the corrected Flt3ITDp.F692F cDNA into 
the same MSCV-CFP retroviral backbone. Briefly, this consisted of the linearized MSCV 
backbone (Fragment 3) and two other fragments generated by PCR from the MSCV-
Flt3ITDp.F692L -CFP plasmid (Fragment 1 and 2). Fragment 2 used a 5’ forward primer 
complimentary to the c.2076T>A SNP (with the appropriate adenine corrected to thymine, 
highlighted in bold capitals below). Fragments 1 and 2 were generated using high fidelity taq 







We assembled the two insert fragments and the linearized vector in a single reaction by 
Gibson Assembly® (Gibson Assembly® Master Mix, NEB) and validated the presence or 




The CellSensor® irf-bla Ba/F3 cell line (#K1654, Invitrogen, Calrsbad). 
Like other Ba/F3 cell lines, the CellSensor® irf-bla Ba/F3 cell line is an IL-3 dependent cell 
line. However, it also contains an additional beta-lactamase reporter gene under the control 
of Stat5 response elements from the IRF1 gene promoter 1. Of note, activation of STAT5 is a 
well reported molecular phenomenon downstream of mutant FLT3-ITD protein2, 3. Using this 
cell line, in conjunction with the LiveBlazer™ FRET B/G substrate (Invitrogen, Calrsbad), 
one can determine the response to a number of agonists (or antagonists) of the IL-3, JAK2 
and STAT5 signalling pathways. Addition of the LiveBlazer™ FRET B/G substrate (excited 
at 409nm) in the absence of an appropriate agonist (such as murine IL-3) results in detection 
at an emission of 520nm (i.e. green). In the presence of the appropriate agonist, expression 
of beta-lactamase results in cleavage of the substrate detectable at an emission of 447nm 







































Supplementary Figure 1. The Flt3 exon 17 c.2076 T>A SNP is present in other Flt3tm1Dgg 
cohorts. 
Sanger sequencing of Homozygous Flt3tm1Dgg tail DNA, covering exon 17 of the Flt3 gene, 
from two independently acquired Flt3tm1Dgg cohorts reveals the presence of the c.2076 T>A 
SNP on the mutant allele. The nucleotide substitution (T>A) and the amino acid (a.a.) 













External cohort 1 
A T T T T A G A A DNA seq: 
a.a. seq: I L E 
External cohort 2 
A T T T T A G A A 
I L E 
 Homozygous Flt3 tm1Dgg Tail DNA 
CFP 











































Supplementary Figure 2. Generation of stably expressing Flt3ITDp.F692L or Flt3ITDp.F692F 
Ba/F3 cells. 
(A) CellSensor® irf-bla Ba/F3 cells were stably transduced with empty MSCV-CFP, MSCV-
Flt3ITD p.F692L-CFP, or the reverted MSCV-Flt3ITD p.F692F-CFP virus. 5 days post transduction 
cells were sorted for expression of CFP using a Mo-FloTM XDP (Beckman Coulter UK Ltd). 
FACS analysis reveals transduced, sorted populations to be >95% CFP positive. (B) FRET 
assays performed on stably transduced, IL-3 independent transformed cell lines show that 
both mutant Flt3 cDNAs activate the Jak/Stat pathway to equivalent levels. FACS shows the 
shift from single positive Green cells (panel i) to the double positive Green/Blue reporter 
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